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ABSTRACT 
Ischemic stroke can cause dopamine efflux that contributes to cell death. Since Kv7 potassium 
channels regulate dopamine release, we investigated the effects of their pharmacological 
modulation on dopamine efflux and neurotoxicity in caudate brain slices undergoing oxygen- and 
glucose- deprivation (OGD). The Kv7 activators retigabine and ICA27243 delayed the onset, and 
decreased the peak level of dopamine efflux induced by OGD; and also decreased OGD-induced 
damage measured by 2,3,5-triphenyltetrazolium chloride (TTC) staining. Retigabine also reduced 
OGD-induced necrotic cell death evaluated by lactate dehydrogenase activity assay. The Kv7 blocker 
linopirdine increased OGD-evoked dopamine efflux and OGD-induced damage, and attenuated the 
effects of retigabine. Quantitative-PCR experiments showed that OGD caused a  ̴6-fold decrease in 
Kv7.2 transcript, while levels of mRNAs encoding for other Kv7 subunits were unaffected; western 
blot experiments showed a parallel reduction in Kv7.2 protein levels. Retigabine also decreased the 
peak level of dopamine efflux induced by L-glutamate, and attenuated the loss of TTC staining 
induced by the excitotoxin. These results suggest a role for Kv7.2 in modulating ischemia-evoked 
caudate damage. 
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INTRODUCTION 
Pharmacological treatments for ischemic stroke mostly rely on recombinant tissue plasminogen 
activator (rt-PA) administration, often showing sub-optimal efficiency1. Therefore, new 
neuroprotective drugs, possibly targeting different mechanisms occurring during ischemic stroke, 
are needed. In stroke and hypoxia, ATP loss results in failure of membrane transporters and ion 
channels, with subsequent membrane depolarization and aberrant neurotransmitters efflux, thus 
amplifying injury2. Increased neuronal excitability seems to be a pathogenic mechanism underlying 
different diseases, such as Alzheimer’s disease and epilepsy; moreover, epidemiologic studies as well 
as experiments on animal models have demonstrated a relationship between ischemia and 
seizures.3 Based on these observations, antiepileptic drugs have been also proposed for stroke 
treatment4. Although glutamate release has been viewed as a main cause of neuronal damage, 
massive release of monoamines, such as dopamine, also occurring immediately following the onset 
of ischemia, can be neurotoxic and thus contribute to cell death5. Moreover, it has been 
demonstrated that chronic methamphetamine administration, as well as striatal injection of 
dopamine caused a marked pre- and post-synaptic neuronal death in rodents6. Dopamine release 
during ischemia is supposed to be a consequence of different mechanisms, such as cell 
depolarization, reversal of dopamine transporters and ATP shortage7. Among the various regulators 
of neurotransmitter release, voltage-gated potassium channels belonging to the Kv7 subfamily have 
emerged as possible targets for hyper-excitability CNS diseases. The Kv7 family comprises five 
members; Kv7.2-Kv7.5 subunits underlie the M current (IKM), a potassium current that reduces 
neuronal excitability, limiting repetitive neuronal firing8. In neurons, IKM is mainly determined by 
hetero-tetramers comprised of Kv7.2 and Kv7.3 subunits; mutations in Kv7.2 and Kv7.3 are 
responsible for inherited and sporadic forms of neonatal-onset epilepsies with wide phenotypic 
heterogeneity, ranging from Benign Familial Neonatal Seizures to epileptic encephalopathy9,10,11. 
Kv7.5 and Kv7.4 subunits also contribute to M-current heterogeneity in neurons, but their role is 
more dominant in non-neuronal tissue, such as inner ear (Kv7.4), smooth muscle (Kv7.4 and Kv7.5)12 
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and skeletal muscle (Kv7.4 and Kv7.5)8,12. Pharmacological modulation of the M-current modifies 
depolarization-induced neurotransmitter release in different brain areas13. In particular the Kv7 
activator retigabine, a recently marketed anti-epileptic drug used as adjunctive treatment in patients 
with refractory epilepsy, was able to decrease dopamine release from isolated striatal nerve 
terminals exposed to high extracellular K+ concentrations14. In addition, while some studies have 
demonstrated that Kv7 activators reduced neuronal damage in hippocampal brain slices15,16, others 
found that M-current activation increased death in hippocampal cultured neurons17.  
The aim of this study was to investigate the potential neuroprotective role of Kv7 channels in an in 
vitro model of ischemia, by evaluating the pharmacological modulation of Kv7 channels on dopamine 
efflux and on neurotoxicity in rat caudate, a region often damaged in ischemic stroke18. 
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MATERIALS AND METHODS 
Animals and brain slices. Adult male Wistar rats (8-10 weeks old) were killed by cervical dislocation, 
in accordance with UK Home Office legislation. The brain was quickly dissected and coronal slices 
(400 μm thick) at the level of the striatum were cut and maintained in artificial cerebrospinal fluid 
(aCSF). The composition of aCSF was (mM): NaCl (126.0), KCl (2.0), KH2PO4 (1.4), MgSO4 (2.0), 
NaHCO3 (26.0), CaCl2 (2.4), (+)-glucose (10.0), bubbled for at least 30 min with 95% O2/5% CO2. 
Once cut, slices were left to equilibrate for 1–4 h at 21±1 ◦C, to allow recovery from any trauma 
associated with slicing7. 
Fast Cyclic Voltammetry (FCV). The FCV recording apparatus comprised a slice chamber (approx. 2 
ml) with the superfusate heated via a thermostatically controlled circulating water bath (Grant, 
Cambridgeshire, UK). Brain slices were continuously superfused with aCSF, at 32.5±0.5ºC, with a flow 
rate of 100 mL/h. We applied a triangular voltage waveform (-1 to +1.4V) to the carbon fibre 
electrode (7 µm diameter x 50 µm length), with a Ag/AgCl reference electrode12; the electrochemical 
signal from carbon-fibre microelectrode, placed into the dorsolateral caudate, was sampled once per 
second, digitized and recorded using Spike7 (CED, Cambridge, UK). An increase in the current at +600 
mV, (the oxidation peak, see Fig 1 inset) together with a corresponding reduction peak at −200 mV is 
indicative of dopamine. 
FCV data analysis. Analysis of data was performed offline using Spike7. Four parameters were 
measured: (1) time to onset of dopamine release from the initiation of OGD superfusion (Ton); (2) 
time taken to reach maximum dopamine release after the onset of release (Tpeak); (3) maximum 
extracellular dopamine concentration (DApeak); and (4) mean rate of dopamine release (DA/Tpeak).  
Experimental protocol for oxygen- and glucose- deprivation and L-glutamate-induced toxicity. 
Slices were allowed to equilibrate for 15 min in normal aCSF, to assess that no spontaneous 
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dopamine release occurred, indicating poor slice health12, then incubated with aCSF containing 0.1% 
DMSO or drug for an additional 15 min before exposure to ischemic or excitotoxic insults. To this 
aim, slices were superfused with oxygen and glucose deprived aCSF (OGD-aCSF, 2mM glucose, 
continuously bubbled with 95% N2/5% CO2) or with 10mM L-Glutamate, respectively. These insults 
were delivered during continued presence of DMSO or test agent until dopamine release occurred 
(for FCV experiments) or for 15 min (for TTC staining and LDH assay).  For qPCR, western blot, TTC 
staining experiments and LDH assay, slices were also reperfused for 30-60 min with normal aCSF 
containing DMSO or drug after OGD, to mimic reperfusion and allow time for cell damage to occur.  
TTC staining. Separate slices were stained with 2,3,5-triphenyltetrazolium chloride (TTC) in aCSF 
(0.125% w/v) at 21±1 ◦C for 30 min and then fixed in 4% paraformaldehyde; photographed and 
analyzed using ImageJ software (http://rsb.info.nih.gov/ij/). Data analysis was performed 
independently by two researchers, one of which was blinded to experimental groups. 
Real time PCR. Total RNA was extracted from brain slices using the RNeasy Mini kit (Qiagen, U.K.) 
and reverse transcribed using Moloney Murine Leukemia Virus (M-MLV; Invitrogen, U.K.). 
Quantitative PCR analysis was performed with the CFX96 machine (Biorad, U.K.), using SYBR green 
master mix and specific primers (PrimerDesign, Ltd., U.K.), followed by melt curve analysis. No 
template controls (NTCs) were run alongside all reactions to assess contamination. Cycle threshold 
(Ct) values were determined and normalized to GAPDH housekeeping gene. Relative abundance of 
each gene of interest was calculated using the 2-ΔΔCt formula.  
Western Blot. Brain slices were homogenized in 100 μL lysis buffer (in mMol/L: 20 Tris base, 137 
NaCl, 2 EDTA, 1% NP40, 10% glycerol, pH 8, and 10 μL/mL protease inhibitor cocktail; Sigma-Aldrich), 
denatured at 95°C for 5 min in the presence of sample buffer and reducing agent (Invitrogen) and 
loaded onto SDS-PAGE gels (4–12% Bis-Tris, Invitrogen), followed by transfer onto a polyvinylidene 
fluoride membrane (Amersham Biosciences). The membrane was then probed with an anti-Kv7.2 
antibody (dilution 1:500; Millipore). Protein bands were visualized with enhanced 
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chemiluminescence (Thermo Scientific) and hyperfilm (Amersham Bioscience). The membranes were 
re-probed for β-actin (1:5000; Sigma-Aldrich, A1978), used as loading control. Bands were quantified 
with Image J.  
LDH assay. Neuronal necrotic damage was assessed by measuring lactate dehydrogenase (LDH) 
activity in the incubation medium, using a specific kit and following manufacturer’s instructions 
(Abcam, Cambridge, U.K.). Briefly, slices were incubated in 24-well plates and exposed to normal- 
and OGD-aCSF, in the presence of 0.1% DMSO or drug, as described above. 50 μL of incubation 
medium were taken at different time point (30 and 60 min of reoxygenation period) and mixed with 
reaction buffer, in the presence of a substrate for LDH. NADH generated by LDH activity interacted 
with a specific probe in a colorimetric reaction that can be read at 450 nm in a microplate reader. 
Each sample was assayed in duplicate in a 96-well plate. Absorbance was measured at time 0 and 
after 30 min incubation at 37◦C. LDH activity (mU/mL) was calculated by comparing samples OD 
values to those obtained from known NADH standards. Values were then normalized to protein 
concentration and results are shown as percentage of control slices.  
Drugs. Several drugs with specificity for different Kv7 channel subtypes were tested, in particular: i) 
the pan-Kv7 activator retigabine), opening Kv7.2 and Kv7.3 channels at low concentration (<1 µM); ii) 
ICA27243 , a Kv7.2/Kv7.3-preferring activator, showing 20- to 100-fold lower potency on Kv7.4 and 
Kv7.5; iii) NS15370, a retigabine-analogue able to activate all Kv7 subunits at sub-micromolar 
concentrations. All activators were a kind gift from Prof SP Olesen (Biomedical Sciences Institute, 
University of Copenhagen). The Kv7 blockers XE991 and linopirdine as well as the dopamine D1 
receptor antagonist SCH23390 were from Tocris Bioscience (Cambridge, U.K.). The dopamine D2 
receptor antagonist metoclopramide and L-glutamate were from Sigma-Aldrich. 
Statistics. Data were compared by use of Student’s t tests or one-way ANOVA, with Dunnett’s post-
hoc correction for multiple comparisons. Significance was set at p < 0.05. Values shown are mean ± 
S.E.M. Authors were not blind to treatment groups. 
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RESULTS 
OGD-evoked dopamine efflux. Exposure of striatal slices to OGD evoked dopamine efflux after 715 ± 
36 s (time to onset, Ton). Peak dopamine efflux (DApeak) was 7.2 ± 0.9 μM and time to peak dopamine 
efflux from the onset of dopamine efflux (Tpeak) was 125 ± 12 s. The average rate of dopamine efflux 
(DA/Tpeak) in control slices was 0.11 ± 0.04 μM/s (Fig 1A). The Kv7 activator retigabine (1 µM) delayed 
the onset of dopamine efflux by about 30% and also reduced dopamine peak and the rate of change 
of dopamine efflux by about 40 and 60%, respectively (Fig 1B, black columns). ICA27243 (1 µM), a 
Kv7.2/Kv7.3-preferring activator, reduced dopamine peak by ~60% but it did not significantly affect 
Ton. ICA27243 also reduced Tpeak by ~60%, although dopamine efflux rate was unaffected (Fig 1B, 
white columns). In contrast NS15370 (0.1 µM), a more potent Kv7 opener with respect to retigabine 
doubled the time to reach dopamine peak, reduced the rate of dopamine efflux by ~55%, but did not 
significantly modify Ton or Tpeak (Fig 1B, grey columns). We then tested two different pan-Kv7 
blockers, XE991 and linopirdine (Fig 1C). While 10 µM XE991 did not interfere with OGD-evoked 
dopamine efflux (Fig 1C, black columns), linopirdine at 10 µM evoked a 4-fold increase in peak 
dopamine and rate of dopamine efflux when compared to controls (Fig 1C, white columns). 
Moreover, linopirdine prevented the changes in Ton, DApeak and DA/Tpeak induced by retigabine after 
OGD superfusion (Fig 1D, white columns). 
TTC staining. To further investigate whether Kv7 activators decreased OGD-induced damage, we 
performed TTC staining experiments on brain slices (Fig 2). Retigabine (0.3-10 µM; Fig 2A) and 
ICA27243 (0.1-10 µM; Fig 2B) attenuated the loss of TTC staining in slices exposed to OGD. In 
contrast, exposure of slices to linopirdine (30 μM) enhanced OGD-induced loss of TTC staining, (Fig 
2C). Co-incubation of linopirdine at 10 µM reversed the reduction in the loss of TTC-staining exerted 
by 1 µM retigabine (Fig 2D).  
To evaluate whether dopamine exerts neurotoxic effects via over-stimulation of dopamine 
receptors, we tested the effects of SCH23390 or metoclopramide, D1- and a D2- receptor 
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antagonists respectively on OGD-induced damage. Neither SCH23390 (10 μM) or metoclopramide (1 
μM) prevented the loss of TTC staining in slices exposed to OGD, and these drugs failed to attenuate 
the potentiated neurotoxic effects evoked by linopirdine (30 μM) (Fig 2E-F).   
Lactate dehydrogenase activity. To evaluate the possible molecular mechanisms underlying 
retigabine-induced neuroprotection, we measured lactate dehydrogenase (LDH) activity in the 
incubation medium of slices exposed to OGD, as an index of cell necrosis. In OGD-exposed slices, 
LDH activity was increased by ~80% and ~50% compared to control slices after 30 and 60 min of 
reoxygenation respectively (Fig 3A, white columns); retigabine (1 μM) reduced OGD-induced 
increase of LDH activity at both time points (Fig 3A, grey columns).  
Q-PCR and Western blots. We next evaluated possible changes in Kv7 transcripts expression after 
OGD. Exposure of striatal slices to OGD followed by incubation in normal aCSF caused a̴ 6-fold 
decrease in Kv7.2-transcripts measured by Q-PCR; instead, mRNAs encoding for other Kv7 subunits 
were unaffected (Fig 3B). Western blot experiments showed a reduction also in Kv7.2 protein levels 
(Fig 3C).  
L-glutamate toxicity. To assess whether Kv7 channel activation might exert neuroprotective actions 
in a different model of cytotoxicity, we evaluated the effects of retigabine on both dopamine release 
and cell damage after exposure of brain slices to high concentrations of L-glutamate. Incubation of 
slices with L-glutamate (10 mM) caused dopamine efflux after 354 ± 40s, reaching peak dopamine 
efflux (6.6 ± 1.4 μM)  after 44 ± 13 s. Co-incubation with retigabine (1 μM) caused a ~3-fold increase 
in time to peak and reduced DApeak and DA/Tpeak by  ~70% and ~80% respectively, while it did not 
significantly affect Ton  (Fig 4A). Moreover, retigabine attenuated the loss of TTC staining in slices 
exposed to L-glutamate (Fig 4B).   
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DISCUSSION 
Ionic homeostasis is fundamental for excitable cells such as neurons, since alterations in the 
concentrations of different ionic species are both causes and consequences of different pathological 
processes (apoptosis, cell shrinkage, proteases activation) and diseases. In particular, K+ ion 
imbalance seems to be strictly linked to neuronal dysfunction, also for the pivotal role exerted by 
this ion species in controlling the resting membrane potential and cell excitability. Indeed, hyper-
excitability is a common feature of many diseases such as epilepsy and ischemia; massive 
neurotransmitters release occurs during brain ischemia, possibly due to damage-induced 
depolarisation and/or the rising of intracellular Ca2+ concentrations2. Thus, modulation of K+ channel 
activity has been acknowledged as a possible target for neuroprotection. Among the different 
neurotransmitters, dopamine release has been demonstrated to reach very high levels soon after an 
ischemic insult in the caudate, and also to contribute to neuronal damage5; indeed, depletion of 
dopaminergic nigro-striatal projections has been demonstrated to reduce ischemic damage19. 
Dopamine and related compound such as L-DOPA and 6-OH-DOPA are considered potent excitotoxic 
agents, possibly contributing to neurodegeneration in Parkinson’s and Huntington’s disease20. Given 
the known effect of the antiepileptic drug retigabine in reducing dopamine release14,21, we have 
investigated the possibility that the pharmacological activation of Kv7-mediated currents could exert 
a neuroprotective effect in an in vitro model of ischemia. In particular, we focused on the striatum, a 
region frequently damaged in ischemic stroke in humans and rodent models of stroke, such as 
middle cerebral artery occlusion. In our experiments the Kv7 activator retigabine was able to reduce 
the peak dopamine efflux and to delay OGD-evoked dopamine efflux. These effects occurred at a 
retigabine concentration (1 μM) close to the EC50 for activation of Kv7.2/Kv7.3 heteromers underlying 
M-current8, and to the plasma concentrations achieved in vivo in humans22. Because these aberrant 
dopamine concentrations have been shown to be neurotoxic, reductions in the peak dopamine 
efflux or the rate of dopamine efflux can be considered neuroprotective, as also suggested by TTC 
staining experiments. This view was corroborated by the results of FCV and TTC experiments using 
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ICA27243, a compound with higher selectivity at Kv7.2/Kv7.3 heterotetramers. In addition NS15370 
reduced the time to reach dopamine peak, but did not reproduce the same effects on OGD-evoked 
dopamine efflux obtained with retigabine and ICA27243. However, it should be mentioned that 
NS15370 has a very complex pharmacological profile, showing also Kv7 channel blockade at 
depolarized potentials23, a characteristic that might in part explain the lack of effects on dopamine 
efflux. Blockade of Kv7 channels by linopirdine increased the amplitude and hastened the rate of 
OGD-evoked dopamine efflux; this result was paralleled by the worsening of OGD-induced brain 
damage caused by exposure to linopirdine, although at a concentration (30 µM) higher than that 
able to increase OGD-evoked dopamine efflux. Moreover, linopirdine 10 µM was able to reverse the 
changes in dopamine efflux induced by retigabine, as well as the reduction in TTC staining loss 
induced by the Kv7 activator. In particular, linopirdine prevented the effect on T-on exerted by 
retigabine, although it did not modify this parameter when incubated alone, thus arguing in favour 
of a specific involvement of the M-current. By contrast, the linopirdine-analogue XE-991 (10 µM) did 
not modulate OGD-evoked dopamine efflux, although it was previously demonstrated that it 
increased depolarization-induced dopamine efflux from isolated striatal synaptosomes14 and from 
striatal brain slices21. Differences in the experimental models (isolated terminals/chopped slices 
versus brain slices), as well as in the experimental procedures (KCl- vs OGD-evoked release, pre-
incubation with dopamine re-uptake inhibitors) might explain this discrepancy.  
Despite the well-known neurotoxic effects prompted by high levels of dopamine, the molecular 
mechanisms underlying these actions are not fully understood. Aberrant dopamine levels can induce 
damage through the formation of oxidative metabolites, derived from both spontaneous or enzyme 
mediated dopamine oxidation24,25. In addition, receptor-mediated mechanisms have been proposed 
to explain dopamine-induced neurotoxicity and the possible neuroprotective effects of dopamine D1 
and D2 receptor antagonists have been investigated in several studies26. In our TTC staining 
experiments, both SCH23390 (D1 receptor antagonist) and metoclopramide (D2 receptor antagonist) 
failed to reduce OGD-induced damage and did not revert the enhanced toxicity caused by 
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linopirdine, suggesting that, in our model, brain damage occurred in a dopamine receptor-
independent manner. These results are not surprising, since conflicting evidence are present in the 
literature; indeed, while some studies failed to demonstrate neuroprotection by D1 and or D2 
receptor antagonists, others found that receptor stimulation (mainly the D2 subtype) reduced 
neuronal damage by blocking the apoptotic pathway (for a comprehensive review, see ref 27).  
The neuroprotective action of Kv7 channel activation was confirmed by LDH assay showing that 
incubation with retigabine reduced necrotic death in brain slices exposed to OGD. We also 
investigated whether retigabine could affect the apoptotic pathway; unfortunately, in our 
experimental model, no clear programmed cell death (measured by the evaluation of caspase 3 
activation) occurred after OGD, even after 2 hours of reoxygenation (data not shown). However, it 
should be mentioned that the degree of apoptosis can significantly vary depending on the 
experimental model and type on insult (duration of OGD and re-oxygenation period), being often 
undetectable28. Moreover, in our experimental model, it was not possible to assess cell damage after 
long incubation time, as viability of brain slice was significantly reduced also in control conditions.  
Both qPCR and western blot data showed a selective decrease in Kv7.2 subunit expression after OGD. 
Although we do not know whether this reduction is only a minor consequence of anoxia, or a main 
pathogenic mechanism through which OGD exerts its neurotoxic effects, pharmacological data 
suggest that the activation of channels incorporating Kv7.2 subunits might counteract the changes 
prompted by ischemia and, at least in part, protect from brain damage. In addition, it has been 
demonstrated that in striatal synaptosomes, selective Kv7.2 blockade with a subunit-specific 
antibody was able to completely abolish the effects of retigabine14, suggesting a primary role of 
Kv7.2 subunits as the molecular determinant of M-current in this brain area. Moreover, Kv7.2 and 
Kv7.3 subunits expression levels can be directly regulated by transcription factors such as Sp1 and 
Repressor Element 1-Silencing Transcription factor (REST)29. Neuronal expression of REST is 
upregulated in many neuronal pathological conditions, such as cerebral ischemia30; thus, the 
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possibility exists that modulation of Kv7.2 expression is a primary mechanism to regulate neuronal 
behaviour during pathological CNS conditions characterized by hyper-excitability. Previous studies 
have demonstrated that retigabine was neuroprotective in hippocampal slices, possibly because of 
its anti-oxidant activity15,16.  Although different brain regions have been investigated, the efficacy of 
ICA27243, as well as the reversal of retigabine effects by linopirdine, suggests a neuroprotection 
mediated by M-current activation. The neuroprotective effects of retigabine are further 
corroborated by the results of our experiments using a different trigger for brain damage. Indeed, 
retigabine was able to decrease dopamine release and reduce damage in brain slices exposed to 
high concentrations of L-glutamate. Since massive release of glutamate occurs during stroke thus 
determining excitotoxicity, these results highlight Kv7 channels as an exciting target for stroke. 
Indeed the M-current activates in the range of resting membrane potential, maintaining it below the 
threshold for sodium current activation, thus limiting repetitive firing after sustained stimulation8. 
Moreover, the M-current can reduce subthreshold excitability, representing a “high-pass filter” for 
triggers arriving to the axon initial segment, a region particularly important for the integration of 
stimuli converging to the neuron; interestingly, Kv7.2 channels are robustly expressed in this region 
of the neuron31. In this regard, the M-current seems to be a major determinant of intrinsic neuronal 
firing characteristics32,33 and its activation might exert beneficial effects not only at pre-synaptic level 
(reduction of neurotransmitter release) but also at post-synaptic and axonal level (decreased 
neuronal excitability). In this scenario, retigabine, by causing a leftward shift in the voltage-
dependence of Kv7 channels, facilitates channel opening at more depolarized potentials, thus 
impeding neuronal depolarization and prevent ischemia-induced hyperexcitability.  
During ischemia, lack of oxygen leads the damaged tissue to switch to anaerobic processes, lactic 
acid production and subsequent acidosis. A decrease in pH has been demonstrated to reduce 
Kv7.2/Kv7.3-mediated currents34; although we did not measure pH in the extracellular fluid or in the 
brain slices, in similar voltammetric experiments in rodent brain slice changes in pH due to local 
electrical stimulation of the brain slice have been observed35. Nevertheless, the possibility exists 
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that, due to the continuous perfusion system used, H+ has largely been washed away and the M-
current is artificially up-regulated in our experiments. Lactate has been proposed as a 
neuroprotective agent, based on the “astrocyte-neuron lactate shuttle hypothesis” suggesting that 
astrocytes can supply lactate as an alternative, possibly the last, energetic substrate to neurons 
through monocarboxylate transporters (MCT) during sustained neuronal activity36. Moreover, 
blockade of the lactate transporter exacerbates damage induced by glutamate37 and exogenous 
lactate can reduce brain damage in in vitro and in vivo models of ischemia38. These data are 
apparently in contradiction with our hypothesis, as lactate production and subsequent acidosis 
decreases Kv7 currents, thus suggesting that Kv7 activation should be neurotoxic. However, lactate 
administration does not seem to modify pH, even at high concentration, in contrast to lactic acid38,39. 
Moreover, endogenous lactate production can be limited by MCT activity which, when saturated, 
can lead to the accumulation of lactic acid and consequent acidosis. Finally, the evidence concerning 
the neuroprotective effects of lactate is conflicting, as other studies have found that reducing lactate 
levels can be neuroprotective and that regional acidosis enhances brain damage40. We do not know 
whether, given the complex functional changes produced by ischemia (involving not only acidosis 
but lactate production also, see below), the protective effects herein reported for Kv7 activators in 
an ex-vivo slice model would be more or less pronounced in vivo. However, the idea that increasing 
Kv7 channel activity can be neuroprotective is further confirmed by research published while this 
manuscript was under review41. The authors found that retigabine and two new Kv7 activators 
reduced infarct size and functional deficits in two in vivo models of stroke. 
Taken together, our data suggest that the M-current activation counteracts the OGD- and 
glutamate-induced efflux of dopamine and subsequent neurotoxicity. This suggests that, in addition 
to increasing cerebral blood flow which follows cerebral arteries vasodilation42, M-current openers 
might provide direct parenchymal protection. Such a dual mechanism of action might represent a 
new strategy for neuroprotection in stroke.  
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TITLES AND LEGENDS TO FIGURES 
FIGURE 1. Effects of Kv7-acting drugs on OGD-induced dopamine efflux. (A) Representative 
experiments showing dopamine efflux elicited by OGD in the presence of vehicle (top trace) and 1 
µM retigabine (bottom trace); the arrow indicate the onset of dopamine efflux. The inset shows the 
cyclic voltammogram obtained by plotting the faradaic current against the input voltage. Faradaic 
currents are obtained by subtracting the signal recorded at the carbon fiber electrode in the absence 
of dopamine from the signal in the presence of dopamine. Peaks due to the oxidation (OX) and 
reduction (RED) of dopamine are indicated. (B-C) Effects of Kv7 activators (B: retigabine, ICA27243 
and NS15370), and blockers (C: XE-991 and linopirdine) on time to onset, time to peak, maximum 
extracellular dopamine concentration and mean rate of dopamine efflux. (D) Effects of 1 µM 
retigabine alone (black columns) or co-incubated with 10 µM linopirdine (white columns) on 
dopamine efflux parameters. Data are expressed as percentage of DMSO-treated slices (controls, 
represented by the dashed line). Values are mean ± S.E.M of 5-9 slices from 5-6 rats. *p < 0.05 
FIGURE 2. Effects of Kv7-acting drugs and dopamine receptor antagonists on OGD-induced toxicity 
measured by TTC staining. (A-C) Effects on TTC staining exerted by increasing concentrations of 
retigabine (A), ICA27243 (B) and linopirdine (C) in OGD-exposed brain slices, as indicated. Data from 
vehicle treated slices are represented with white columns. (D) Effects on TTC staining of 1µM 
retigabine alone (white columns) or co-incubated with 10µM linopirdine (light grey columns). (E-F) 
Effects on TTC staining in OGD-exposed slices of 10 µM SCH23390 (E) and 1 µM metoclopramide (F) 
used alone and co-incubated with 30 µM linopirdine. Data from vehicle treated slices are 
represented with white columns. All data are expressed as percentage of normal aCSF-incubated 
slices (control, black columns). Each bar represents the mean ± S.E.M of 4-7 slices from 4-5 rats. *p < 
0.05.  
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FIGURE 3. Effects of retigabine on OGD-induced necrosis and effects of OGD on Kv7 subunits 
expression (A) Bar graph showing LDH activity measured in the incubation medium in brain slices 
exposed to normal aCSF (control, black columns),  to OGD+vehicle (white columns) or to OGD+1 µM 
retigabine, after 30 and 60 min of reoxygenation. Data are expressed as percentage of respective 
control. Each bar represents the mean ± S.E.M. of 8-10 slices from 4-5 rats. *p < 0.05.  (B) Q-PCR 
experiments showing mRNA levels encoding for Kv7 subunits in striatal slices exposed to normal aCSF 
(control) or OGD. Data are normalized to housekeeping gene gapdh and expressed as relative to the 
average of controls, using the 2-ΔΔCt formula. Values are mean ± S.E.M of 4-6 slices. *p < 0.05. (C) 
Western blot analysis for Kv7.2 protein expression on total lysates from control- or OGD-treated 
slices. The inset shows a representative blot for Kv7.2 and β-actin. The approximate molecular mass 
for each of these proteins (expressed in kDa) is shown on the left. Bar graph shows the 
quantification of the averaged OD values for the Kv7.2 bands, normalized to the OD value for β-actin, 
in both normal aCSF (black columns) and OGD-exposed (white columns) slices. *p < 0.05 vs. 
respective control; n=5 for both control- and OGD-exposed slices. 
FIGURE 4. Effects of retigabine on L-glutamate-induced dopamine release and toxicity. (A) FCV 
experiments showing the effects of 1 µM retigabine on time to onset, time to peak, maximum 
extracellular dopamine concentration and mean rate of dopamine efflux in brain slices exposed to 
10 mM L-glutamate. Data are expressed as percentage of DMSO-treated slices (controls, black 
columns). Values are mean ± S.E.M of 5-9 slices from 5-6 rats. *p < 0.05. The inset shows 
representative experiments of dopamine efflux elicited by OGD in the presence of vehicle (top trace) 
and 1 µM retigabine (bottom trace); the arrow indicate the onset of dopamine peak. The cyclic 
voltammogram generated by plotting the faradaic current against the input voltage is also shown. 
Peaks due to the oxidation (OX) and reduction (RED) of dopamine are indicated. (B) Bar graph 
showing the effects of exposure to 10 mM L-glutamate in the presence of DMSO (white column) or 1 
µM retigabine (grey column). Data are expressed as percentage of DMSO-treated slices (control with 
no L-glutamate, black column). Values are mean ± S.E.M of 6-8 slices from 3-4 rats. *p < 0.05. 
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